Breaking News Instant updates and real-time market news.

KALV

KalVista

$11.58

0.55 (4.99%)

04:55
10/24/19
10/24
04:55
10/24/19
04:55

KalVista management to meet with Needham

Meeting to be held in Portland and Salt Lake City on October 24 hosted by Needham.

  • 24

    Oct

KALV KalVista
$11.58

0.55 (4.99%)

05/15/19
ROTH
05/15/19
NO CHANGE
Target $30
ROTH
Buy
KalVista price target raised to $30 from $25 at Roth Capital
Roth Capital analyst Jotin Marango raised his price target for KalVista to $30 from $25 ahead of a string of potentially value-driving events in the next six months, including first clinical peek at a novel agent around mid-year DME Phase 2 data in the second half of 2019, and HAE Phase 2 data in the fourth quarter. The analyst reiterates a Buy rating on the shares.
07/29/19
LEER
07/29/19
INITIATION
Target $31
LEER
Outperform
KalVista initiated with an Outperform at SVB Leerink
SVB Leerink analyst Dae Gon Ha initiated KalVista with an Outperform and 31 price target.
08/19/19
CANT
08/19/19
NO CHANGE
Target $32
CANT
Overweight
KalVista's 2H could be 'tranformational' for PKal-inhib, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on KalVista with a $32 price target. After hosting the company for investor meetings, Duncan tells investors in a research note that he came away with enhanced conviction for its broad plasma kallikrein inhibitor platform. In his view, PKal-inhibitor is a well-established MoA for acute treatment of HAE attacks and says data with KVD900 in the second half of the year could address investor concerns about the viability of an oral option, and risk- reduce KVD900 ushering-in a new treatment paradigm in acute HAE, currently dominated by IV/injectable biologics. He feels the second half of the year could prove "tranformational" for the PKal-inhibitor platform.
10/14/19
ROTH
10/14/19
NO CHANGE
ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Commenting on the Ophthalmology space, Roth Capital analyst Zegbeh Jallah highlights her conviction for stronger valuations, driven by the increasing number of companies with innovative pipelines, and pending changes at both the FDA and CMS. The analyst suspects that these changes could lead to more wins in the space, which could drive valuations. Further, she cautions investors to keep "their eyes peeled on developments in the space." Jallah sees this as possible relevant for KalVista (KALV), Regenxbio (RGNX), Kala Pharmaceuticals (KALA), Kodiak Sciences (KOD), Regeneron (REGN), Aerie Pharmaceuticals (AERI), Applied Genetic (AGTC), Aldeyra (ALDX), Adverum Biotechnologies (ADVM), Clearside Biomedical (CLSD), Ocugen (OCGN), and many others.

TODAY'S FREE FLY STORIES

XLV

Health Care Select Sector SPDR

$94.75

-0.39 (-0.41%)

08:22
11/12/19
11/12
08:22
11/12/19
08:22
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$158.76

-0.33 (-0.21%)

08:22
11/12/19
11/12
08:22
11/12/19
08:22
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$3.27

0.09 (2.83%)

08:21
11/12/19
11/12
08:21
11/12/19
08:21
Hot Stocks
Aptinyx initiates two phase 2 studies of NYX-2925 »

Aptinyx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DIA

Diamonds Fund ETF

$277.12

0.08 (0.03%)

08:21
11/12/19
11/12
08:21
11/12/19
08:21
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$308.35

-0.6 (-0.19%)

08:21
11/12/19
11/12
08:21
11/12/19
08:21
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$29.77

-0.065 (-0.22%)

08:21
11/12/19
11/12
08:21
11/12/19
08:21
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$132.63

-0.56 (-0.42%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLMT

Calumet Specialty Products

$3.77

0.45 (13.55%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Hot Stocks
Calumet Specialty Products sees FY19 Cap-Ex $80M-$90M »

Through the Q3 total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GILT

Gilat Satellite

$7.65

-0.22 (-2.80%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Hot Stocks
Gilat Satellite awarded $10M for five-year project for 3G/4G backhaul services »

Gilat Satellite Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

EXEL

Exelixis

$15.55

-0.215 (-1.36%)

, IPSEY

Ipsen

$0.00

(0.00%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Hot Stocks
Exelixis to receive $2M from Health Canada approval of Ipsen's Cabometyx »

Exelixis (EXEL) announced…

EXEL

Exelixis

$15.55

-0.215 (-1.36%)

IPSEY

Ipsen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$200.95

-0.3 (-0.15%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$0.00

(0.00%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLMT

Calumet Specialty Products

$3.77

0.45 (13.55%)

08:20
11/12/19
11/12
08:20
11/12/19
08:20
Earnings
Calumet Specialty Products reports Q3 adjusted EPS 9c, consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

EDIT

Editas Medicine

$20.38

-0.17 (-0.83%)

08:19
11/12/19
11/12
08:19
11/12/19
08:19
Earnings
Editas Medicine reports Q3 EPS (66c) vs. (32c) last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

JWCAF

James E Wagner Cultivation

$0.00

(0.00%)

08:17
11/12/19
11/12
08:17
11/12/19
08:17
Hot Stocks
James E Wagner Cultivation enters into cannabis vape program agreement »

James E. Wagner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$234.23

-0.855 (-0.36%)

08:17
11/12/19
11/12
08:17
11/12/19
08:17
Hot Stocks
Canadian Pacific achieves transportation record in October »

Canadian Pacific moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ALNY

Alnylam

$92.31

-0.57 (-0.61%)

08:17
11/12/19
11/12
08:17
11/12/19
08:17
Conference/Events
Alnylam management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Nov

  • 07

    Dec

  • 04

    Feb

HOLX

Hologic

$45.63

-0.92 (-1.98%)

08:17
11/12/19
11/12
08:17
11/12/19
08:17
Hot Stocks
Hologic announces FDA approval of 3DQuorum »

Hologic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

SNCR

Synchronoss

$4.01

-0.26 (-6.09%)

, T

AT&T

$39.37

(0.00%)

08:16
11/12/19
11/12
08:16
11/12/19
08:16
Hot Stocks
Synchronoss collaborates with CCMI joint venture »

Synchronoss Technologies…

SNCR

Synchronoss

$4.01

-0.26 (-6.09%)

T

AT&T

$39.37

(0.00%)

S

Sprint

$5.91

-0.2 (-3.27%)

TMUS

T-Mobile

$79.64

-1.28 (-1.58%)

VZ

Verizon

$59.61

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

GILD

Gilead

$64.66

-0.68 (-1.04%)

08:15
11/12/19
11/12
08:15
11/12/19
08:15
Initiation
Gilead initiated  »

Gilead initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AFG

American Financial Group

$109.84

-0.75 (-0.68%)

08:14
11/12/19
11/12
08:14
11/12/19
08:14
Conference/Events
American Financial Group management to meet with Sandler ONeill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SCPH

scPharmaceuticals

$5.26

0.11 (2.14%)

08:13
11/12/19
11/12
08:13
11/12/19
08:13
Hot Stocks
scPharmaceuticals expects 2019 cash, cash equivalents $65M-$70M »

Based on its current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCPH

scPharmaceuticals

$5.26

0.11 (2.14%)

08:12
11/12/19
11/12
08:12
11/12/19
08:12
Earnings
scPharmaceuticals reports Q3 EPS (31c), consensus (45c) »

"We continue to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$16.90

-0.58 (-3.32%)

08:12
11/12/19
11/12
08:12
11/12/19
08:12
Hot Stocks
Amarin jumps as FDA posts documents for Vascepa advisory committee meeting »

Shares of Amarin (AMRN)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.